ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 65 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $137 | -89.6% | 22,691 | -86.7% | 0.00% | -80.0% |
| Q2 2023 | $1,322 | +77.7% | 170,488 | +30.5% | 0.01% | +66.7% |
| Q1 2023 | $744 | -1.1% | 130,655 | +2.2% | 0.00% | -25.0% |
| Q4 2022 | $752 | -99.8% | 127,851 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $408,000 | -20.2% | 127,851 | +11.9% | 0.00% | -33.3% |
| Q2 2022 | $511,000 | +1662.1% | 114,216 | +1974.0% | 0.00% | – |
| Q1 2022 | $29,000 | – | 5,507 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |